Allergan (NYSE: AGN) is lower on Friday’s session following a new FDA document which discusses generic cyclosporine ophthalmic emulsion (generic Restasis).
To read the full document (in pdf form), click here.
Shares pf Allergan are down 5.4 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items – JOIN NOW *NEW – Download StreetInsider’s FREE iPhone and iPad App – Click Here begin ad tag (tile=12) — End ad tag —